GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Shiller PE Ratio

Kintara Therapeutics (STU:3DMA) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kintara Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Kintara Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Shiller PE Ratio Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintara Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Kintara Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Shiller PE Ratio falls into.



Kintara Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kintara Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Kintara Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.046/131.7762*131.7762
=-0.046

Current CPI (Mar. 2024) = 131.7762.

Kintara Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 14.720 100.560 19.290
201409 -62.080 100.428 -81.458
201412 -48.660 99.070 -64.724
201503 -73.920 99.621 -97.779
201506 -8.910 100.684 -11.662
201509 -66.825 100.392 -87.716
201512 -110.160 99.792 -145.467
201603 -44.900 100.470 -58.890
201606 -146.850 101.688 -190.301
201609 -102.465 101.861 -132.558
201612 -61.620 101.863 -79.716
201703 -84.150 102.862 -107.804
201706 -89.000 103.349 -113.480
201709 -75.510 104.136 -95.553
201712 -59.150 104.011 -74.940
201803 -53.120 105.290 -66.483
201806 -43.228 106.317 -53.580
201809 -37.708 106.507 -46.655
201812 -32.962 105.998 -40.978
201903 -29.648 107.251 -36.428
201906 -39.383 108.070 -48.022
201909 -9.695 108.329 -11.793
201912 -6.750 108.420 -8.204
202003 -7.692 108.902 -9.308
202006 -15.540 108.767 -18.827
202009 -56.459 109.815 -67.750
202012 -9.042 109.897 -10.842
202103 -9.660 111.754 -11.391
202106 -5.395 114.631 -6.202
202109 -10.625 115.734 -12.098
202112 -5.372 117.630 -6.018
202203 -4.949 121.301 -5.376
202206 -3.226 125.017 -3.400
202209 -3.424 125.227 -3.603
202212 -1.982 125.222 -2.086
202303 -1.812 127.348 -1.875
202306 -1.800 128.729 -1.843
202309 -1.715 129.860 -1.740
202312 -0.220 129.419 -0.224
202403 -0.046 131.776 -0.046

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kintara Therapeutics  (STU:3DMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kintara Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (STU:3DMA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines